FDASRA Act of 2022

12/29/2022, 6:33 PM

Food and Drug Administration Simple Reauthorization Act of 2022 or the FDASRA Act of 2022

This bill reauthorizes the authority of the Food and Drug Administration to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts.

Congress
117
Number
S - 4535
Introduced on
2022-07-14
# Amendments
0
Sponsors
+5

Variations and Revisions

7/14/2022
Text
PDF
XML

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Food and Drug Administration Simple Reauthorization Act of 2022 or the FDASRA Act of 2022

This bill reauthorizes the authority of the Food and Drug Administration to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts.

Alternative Names
Official Title as IntroducedA bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Policy Areas
Health

Comments

Related

Bill Update Alert:  FDASLA Act of 2022
Bill Update Alert:  Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

Recent Activity

Latest Summary11/21/2022

Food and Drug Administration Simple Reauthorization Act of 2022 or the FDASRA Act of 2022

This bill reauthorizes the authority of the Food and Drug Administration to collect certain fees related to drugs, medical devices, and biosim...

Latest Action7/14/2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.